Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Naringin on the Pharmacokinetics of Nifedipine in Rabbits

토끼에서 나린진이 니페디핀의 약물동태에 미치는 영향

  • Published : 2005.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

The pharmacokinetics of oral nifedipine (5 mg/kg) was studied in rabbits given after or simultaneously with naringin (1.5, 7.5 and 15 mg/kg, respectively). The area under the plasma concentration-time curve (AUC) and the peak concentration $(C_{max})$ of nifedipine coadministered or pretreated with naringin were significantly increased (p < 0.05, coad.; p < 0.01, pret.) compared with the control group. The absolute bioavailability (AB%) of nifedipine was significantly (p < 0.05, coad.; p < 0.01, pret.) higher by 22.3 - 28.1 % compared to the control (17.9%). The relative bioavailability (RB%) of nifedipine was higher by 1.24 - 1.43 times (coad.) and 1.32 -1.57 times (pret.) than those of the control, showing that preatreatrnent of naringin was more effective than that of the coadministration of naringin. Naringin did not show significant effect on the Tmax and $t_{1/2}$ of nifedipine. It is suggested that naringin may alter pharmacokinetic paramiters of nifedipine by inhibition of P-glycoprotein efflux pump and its first-pass metabolism. The dosage of nifedipine should be adjusted when it is administered with naringin in a clinical situation.

Keywords

References

  1. P.D. Henry, Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem, Am. J. Cardiol., 46, 1047-1058 (1980) https://doi.org/10.1016/0002-9149(80)90366-5
  2. E.M. Sorkin, S.P. Clissold and R.N. Brogden, Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders, Drugs., 30, 182-274 (1985) https://doi.org/10.2165/00003495-198530030-00002
  3. D.G. Walter, B.S. Gruchy, A.G. Renwick and C.F. George, The first pass metabolism of nifedipine in man, Br. J. Clin. Pharmacol., 18, 951-954 (1984) https://doi.org/10.1111/j.1365-2125.1984.tb02569.x
  4. K.D. Raemsch and J.C. Sommer, Pharmacokinetics and metabolism of nifedipine, Hypertension., 5, 18-24 (1983)
  5. F.P. Guengerich, W.R. Brian and M. Iwasaki, et al., Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 lIIA4, J. Med. Chem., 4, 1838-1844 (1991)
  6. C. Iribarne, L.G. Dreano, J.F. Bardou, G. Menez and F. Berthou, Interaction of methadone with substrates of human hepatic cytochrome P450 3A4, Toxicology., 117, 13-23 (1997) https://doi.org/10.1016/S0300-483X(96)03549-4
  7. P.B. Watkins, S.A. Wrighton, E.G. Schuetz, D.T. Molowa and P.S. Guzelian, Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, J. Clin. Invest., 80, 1029-1036 (1987) https://doi.org/10.1172/JCI113156
  8. J.C. Kolars, P. Schmiedlin-Ren, W.O. Dobbins 3rd, J. Schuetz, S.A. Wrighton and P.B. Watkins, Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology., 102, 1186-1198 (1992)
  9. M.M. Gottesman and I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993) https://doi.org/10.1146/annurev.bi.62.070193.002125
  10. L.-S.L. Gan, M.A. Moseley, B. Khosla, P.F. Augustijns, T.P. Bradshaw, R.W. Hendren and D.R. Thakker, CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos., 24, 344-349 (1996)
  11. P.B. Watkins, The barrier function of CYP3A4 and Pglycoprotein in the small bowel, Adv. Drug Deliv. Rev., 27, 161-170 (1996) https://doi.org/10.1016/S0169-409X(97)00041-0
  12. V.H. Wacher, J.A. Silverman, Y. Zhang and L.Z. Benet, Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics, J. Pharm. Sci., 87, 1322-1330 (1998) https://doi.org/10.1021/js980082d
  13. K. Ito, H. Kusuhara and Y. Sugiyama, Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach, Pharm. Res., 16, 225-231 (1999) https://doi.org/10.1023/A:1018872207437
  14. P.M. Chaudhary, and I.B. Robinson, Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells, Cell., 66, 85-94 (1991) https://doi.org/10.1016/0092-8674(91)90141-K
  15. J. Van Asperen, O. Van Tellingen, A. Sparreboom, A.H. Schinkel, P. Borst, W.J. Nooijen and J.H. Beijnen, Enhanced oral bilavailability of diltiazem in mice treated with the pglycoprotein blocker, Br. J. Cancer., 76, 1181-1183 (1997) https://doi.org/10.1038/bjc.1997.530
  16. J.L. Biedler and H. Riehm, Cellular resistance to actinomycin D in Chinese hamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies, Cancer Res., 30, 1174-1184 (1970)
  17. J.M. Ford, Modulators of multidrug resistance preclinical studies, Hematol. Oncol. Clin. N. Am., 9, 337-361 (1995)
  18. J.P. Fruehauf and A. Manetta, Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDRI expression, Contrib. Gynecol. Obstet., 19, 39-52 (1994)
  19. T. Endo, O. Kimura and M. Sakata, Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK, Toxicol. Appl. Pharmacol., 185, 166-171 (2002) https://doi.org/10.1006/taap.2002.9533
  20. N. Hokama, N. Hobara, M. Sakai, H. Kameya, S. Ohshiro and M. Sakanashi, Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats, J. Pharm. Pharmacol., 54, 821-825 (2002) https://doi.org/10.1211/0022357021778998
  21. R.A. Dixon and C. Steele, Flavonoids and isoflavonoids-gold mine for metabolic engineering. Trends Plant Sci., 4, 394-400 (1999) https://doi.org/10.1016/S1360-1385(99)01471-5
  22. R.J. Nijveldt, E. van Nood, D.E.C. van Hoorn, P.G. Boelens, K. van Norren and P.A.M. van Leeuwen, Flavonoids: A review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr., 74, 418-425 (2001)
  23. H. Doostdar, M.D. Burke and R.T. Mayer, Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology., 144, 31-38 (2000) https://doi.org/10.1016/S0300-483X(99)00215-2
  24. P. Hodek, P. Trefil and M. Stiborova, Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 139, 1-21 (2002) https://doi.org/10.1016/S0009-2797(01)00285-X
  25. J. Dupuy, G. Larrieu, J.F. Sutra, A. Lespine and M. Alvinerie, Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: Quercetin. Vet. Parasitol., 112, 337-347 (2003) https://doi.org/10.1016/S0304-4017(03)00008-6
  26. H.A. Bardelmeijer, J.H. Beijnen, K.R. Brouwer, H. Rosing, W.J. Nooijen, J.H. Schellens and O. van Tellingen, Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res., 6, 4416-4421 (2000)
  27. The Merck Index, 12th Edition, Merck and Company., Rahway, USA., 6512 (1996)
  28. D.H. Kim, E.A. Jung, I.S. Sohng, J.A. Han, T.H.Kim and M.J. Han, Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res., 21, 17-23 (1998) https://doi.org/10.1007/BF03216747
  29. H. Zhang, C.W. Wong, P.G. Coville and S. Wanwimolruk, Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Meta. Drug Interact., 17, 351-363 (2000)
  30. P.C. Ho, D.J. Saville and S. Wanwimolruk, Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci., 4, 217-227 (2001)
  31. H. Takanaga, A. Ohnishi, H. Matsuo and Y. Sawada, Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull., 21, 1062-1066 (1998) https://doi.org/10.1248/bpb.21.1062
  32. V.A. Eagling, L. Profit and D.J. Back, Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol., 48, 543-552 (1999) https://doi.org/10.1046/j.1365-2125.1999.00052.x
  33. J.S. Choi and S.C. Shin, Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int. J. Pharm., 23, 149-156 (2005)
  34. J.S. Grundy, R. Kherani and R.T. Foster, Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection, J. Chromatogr. B. Biomed. Appl., 654, 146-151 (1994) https://doi.org/10.1016/0378-4347(93)E0449-Z
  35. M.L. Rocci and W.J. Jusko, LAGRAN program for area and moments in Pharmacokinetic analysis. Computer Programs in Biomedicine., 16, 203-209 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
  36. M. M. Gottesman and I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385 (1993) https://doi.org/10.1146/annurev.bi.62.070193.002125
  37. K. Ito, H. Kusuhara and Y. Sugiyama, Effects of intestinal CYP 3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res., 16, 225 (1999) https://doi.org/10.1023/A:1018872207437